Want to see GYRE full AI Analyst Report?

Gyre Therapeutics (GYRE) Price & Analysis

830 Followers

GYRE Stock Chart & Stats

$6.65

-$0.07(-1.16%)

At close: Jul 24 4:00 PM EDT

$6.65

-$0.07(-1.16%)

Day’s Range― - ―

52-Week Range$5.44 - $9.14

Previous Close$5.94

Volume33.77K

Average Volume (3M)180.38K

Market Cap

$654.23M

Enterprise Value$648.81M

Total Cash (Recent Filing)$74.80M

Total Debt (Recent Filing)$3.42M

Price to Earnings (P/E)―

Beta1.71

Next Earnings

Nov 18, 2026

EPS Estimate

-0.12

Next Dividend Ex-DateN/A

Dividend Yield642.31%

Share Statistics

EPS (TTM)-0.20

Shares Outstanding106,033,760

10 Day Avg. Volume123,362

30 Day Avg. Volume180,375

Financial Highlights & Ratios

PEG Ratio-2.10

Price to Book (P/B)5.95

Price to Sales (P/S)5.41

P/FCF Ratio-3.50K

Enterprise Value/Market Cap0.99

Enterprise Value/Revenue5.43

Enterprise Value/Gross Profit5.76

Enterprise Value/Ebitda-51.46

Forecast

1Y Price Target

$19.00

Price Target Upside185.71% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

EPS Forecast (FY)-0.4

Revenue Forecast (FY)$109.50M

Bulls Say, Bears Say

Bulls Say

High Gross MarginA roughly 94% TTM gross margin shows that the commercial offering retains substantial value after direct costs. If maintained, this provides room to fund research, regulatory work, and commercialization while supporting resilience as the company develops additional therapies.

Conservative Balance SheetVery low leverage reduces near-term financing pressure and leaves more flexibility to support clinical development, regulatory activity, and commercial investment. The sizable equity base also provides a stronger foundation than a highly debt-dependent structure during biotech development cycles.

Revenue-Funded Pipeline StrategyUsing established China operations to help fund discovery and early development can reduce reliance on external capital and make pipeline investment more selective. The model links current commercialization with future oncology, inflammatory, and fibrosis opportunities over several development cycles.

Bears Say

Return To Net LossThe shift from prior profitability to a TTM net loss indicates that operating costs are currently absorbing the benefit of strong gross profitability. Persistent losses could constrain internally funded development and make future earnings power less predictable until expenses normalize.

Unreliable Operating Cash ConversionNegative TTM operating cash flow means reported commercial economics are not yet converting consistently into cash from core operations. The uneven history increases execution risk because development and commercialization may require funding before operating inflows become dependable.

Earnings And Equity VolatilityNegative TTM return on equity and the prior period of negative equity show that the company’s capital base and shareholder returns can change sharply with earnings outcomes. This volatility lowers confidence in the durability of returns even with currently low leverage.

Gyre Therapeutics News

Gyre Therapeutics Secures CEO and CFO with New Contracts

An announcement from Gyre Therapeutics ( ($GYRE) ) is now available. On October 16, 2026, Gyre Therapeutics entered...

1d ago

GYRE

Gyre Therapeutics Highlights Capital-Efficient Global Development Strategy

Gyre Therapeutics ( ($GYRE) ) just unveiled an announcement. On September 1, 2026, Gyre Therapeutics made an updated...

2M ago

GYRE

Gyre Therapeutics unveils capital-efficient global development strategy

An update from Gyre Therapeutics ( ($GYRE) ) is now available. On August 26, 2026, Gyre Therapeutics released...

2M ago

GYRE

Thin Float, Heavy Overhang: Analyst Warns Gyre Therapeutics’ Concentrated Ownership and Pledged Shares Heighten Liquidity and Control Risks

Gyre Therapeutics Inc (GYRE) has disclosed a new risk, in the Share Price & Shareholder Rights category. The...

3M ago

GYRE

Gyre Therapeutics Strengthens Board with New Director Appointments

Gyre Therapeutics ( ($GYRE) ) has issued an announcement. On July 10, 2026, Gyre Therapeutics’ board appointed Chief...

3M ago

GYRE

Gyre Therapeutics files to sell 30.22M shares of common stock for holders

06:03 EDT Gyre Therapeutics (GYRE) files to sell 30.22M shares of common stock for holders Published first on...

4M ago

GYRE

Gyre Therapeutics Shareholders Approve Directors and Governance Measures

The latest announcement is out from Gyre Therapeutics ( ($GYRE) ). On June 10, 2026, Gyre Therapeutics, Inc....

4M ago

GYRE

Gyre Therapeutics Updates Post-Cullgen Acquisition Growth Strategy

Gyre Therapeutics ( ($GYRE) ) has issued an announcement. On June 1, 2026, Gyre Therapeutics released an updated...

5M ago

GYRE

Gyre Therapeutics Highlights Cullgen Acquisition and Pipeline Expansion

Gyre Therapeutics ( ($GYRE) ) has issued an announcement. On May 15, 2026, Gyre Therapeutics planned to present...

5M ago

GYRE

Gyre Therapeutics’ F351 NDA Accepted for Priority Review

Gyre Therapeutics ( ($GYRE) ) has provided an announcement. On May 12, 2026, Gyre Therapeutics announced that China’s...

5M ago

GYRE

Gyre Therapeutics announces China NMPA acceptance of F351 NDA

Gyre Therapeutics (GYRE) announced that the Center for Drug Evaluation, or CDE, of China’s National Medical Products Administration,...

5M ago

GYRE

Gyre Therapeutics reports Q1 EPS (10c) vs. 0c last year

Reports Q1 revenue $22.52M, consensus $31.61M. “Building on our successful pre-NDA meeting with China’s CDE at the beginning...

6M ago

GYRE

GYRE Upcoming Earnings Report: What to Expect?

Gyre Therapeutics Inc (GYRE) is scheduled to report 1st quarter earnings on 05/08/2026. Regarding Q1 estimates, Wall Street...

6M ago

GYRE

Gyre Therapeutics’ liver fibrosis candidate granted priority review in China

Gyre Therapeutics (GYRE) announced that the Center for Drug Evaluation of China’s National Medical Products Administration, or NMPA,...

7M ago

GYRE

GYRE FAQ

What was Gyre Therapeutics’s price range in the past 12 months?

Gyre Therapeutics lowest stock price was $5.44 and its highest was $9.14 in the past 12 months.

What is Gyre Therapeutics’s market cap?

Gyre Therapeutics’s market cap is $654.23M.

When is Gyre Therapeutics’s upcoming earnings report date?

Gyre Therapeutics’s upcoming earnings report date is Nov 18, 2026 which is in 25 days.

How were Gyre Therapeutics’s earnings last quarter?

Gyre Therapeutics released its earnings results on Aug 07, 2026. The company reported -$0.12 earnings per share for the quarter, missing the consensus estimate of -$0.057 by -$0.063.

Is Gyre Therapeutics overvalued?

According to Wall Street analysts Gyre Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Gyre Therapeutics pay dividends?

Gyre Therapeutics pays a Quarterly dividend of $3.6 which represents an annual dividend yield of 642.31%. See more information on Gyre Therapeutics dividends here

What is Gyre Therapeutics’s EPS estimate?

Gyre Therapeutics’s EPS estimate is -0.12.

How many shares outstanding does Gyre Therapeutics have?

Gyre Therapeutics has 106,033,760 shares outstanding.

What happened to Gyre Therapeutics’s price movement after its last earnings report?

Gyre Therapeutics reported an EPS of -$0.12 in its last earnings report, missing expectations of -$0.057. Following the earnings report the stock price went up 4.219%.

Which hedge fund is a major shareholder of Gyre Therapeutics?

Currently, no hedge funds are holding shares in GYRE

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Gyre Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-15.77%

Trailing 12-Months

Asset Growth

30.53%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Gyre Therapeutics

Gyre Therapeutics, Inc. is a pharmaceutical company dedicated to discovering, advancing, and bringing to market small-molecule drugs that target inflammation and fibrosis in various organs. The company's key anti-fibrotic medication, ETUARY (Pirfenidone), has received approval for treating idiopathic pulmonary fibrosis. Beyond this, ETUARY is also undergoing late-stage (Phase 3) clinical trials for several other conditions, including dermatomyositis and interstitial lung disease linked to systemic sclerosis, pneumoconiosis, and diabetic kidney disease. The company's pipeline further includes F351 (Hydronidone), a compound structurally related to ETUARY. F351 is currently in Phase 3 studies for chronic hepatitis B-induced liver fibrosis and is in Phase 1 trials for liver fibrosis associated with nonalcoholic associated steatohepatitis (NASH). Other programs in development feature F573, which is progressing through Phase 2 studies for acute and acute-on-chronic liver failure. Additionally, two early-stage candidates, F528 and F230, are in preclinical development, focusing on chronic obstructive pulmonary disease (COPD) and pulmonary arterial hypertension (PAH), respectively. Established in 2002, Gyre Therapeutics, Inc. is based in San Diego, California, and operates as a subsidiary of GNI USA, Inc.

Gyre Therapeutics (GYRE) Earnings & Revenues

Historic Earnings Reports

GYRE Stock 12 Month Forecast

Average Price Target

$19.00

▲(185.71% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","21":"$21","8.25":"$8.25","12.5":"$12.5","16.75":"$16.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$20.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":19,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$19.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$18.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,8.25,12.5,16.75,21],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7,8,9,10,11,12,13,14,15,16,17,18,19,{"y":20,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7,7.923076923076923,8.846153846153847,9.76923076923077,10.692307692307693,11.615384615384617,12.538461538461538,13.461538461538462,14.384615384615385,15.307692307692308,16.230769230769234,17.153846153846153,18.076923076923077,{"y":19,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7,7.846153846153846,8.692307692307692,9.538461538461538,10.384615384615385,11.23076923076923,12.076923076923077,12.923076923076923,13.76923076923077,14.615384615384615,15.461538461538462,16.307692307692307,17.153846153846153,{"y":18,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":7.58,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.75,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.67,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.06,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.21,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.76,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.23,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.8,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.81,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.52,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.75,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.47,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >